USE OF PDGF RECEPTOR THYROSINE KINASE INHIBITORS IN THE TREATMENT OF DIABETIC NEFROPATIA.

摘要

Use of a PDGF receptor tyrosine kinase inhibitor of formula I, wherein R1 is 4-pyrazinyl; 1-methyl-1H-pyrrolyl; amino- or amino-C1-7-substituted phenyl, wherein the amino group in each case is free, alkylated or acylated; 1 H-indolyl or 1H-imidazolyl attached to a five-membered ring of carbon atoms; or unsubstituted or substituted C1-7-pyridyl alkyl attached to a ring of a carbon atom and unsubstituted or substituted on the nitrogen atom by an oxygen; R2 and R3 are each independently of the other hydrogen or C1-7 alkyl; one or two of the radicals R4, R5, R6, R7 and R8 are each nitro, fluoro-substituted C1-7 alkoxy or a radical of the formula II -N (R9) -C (= X) - (Y) nR10 (II), wherein R9 is hydrogen or C1-7 alkyl, X is oxo, thio, imino, N-C1-7-imino alkyl, hydroximino or O-C1-7-hydroxyino alkyl, Y is oxygen or the NH group , n is 0 or 1 and R10 is an aliphatic radical having at least 5 carbon atoms, or an aromatic, aromatic-aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or heterocyclic-aliphatic radical, and the remaining radicals R4, R5, R6, R7 and R8 are each independently of the other hydrogen, C1-7 alkyl which is unsubstituted or substituted by a free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by a morpholinyl, or C1-7 alkanoyl, trifluoromethyl, hydroxy free, etherified or esterified, free amino, alkylated or acylated or free or esterified carboxy, or a salt of said compounds having at least one salt forming group, for the preparation ation of a medication for the treatment of diabetic nephropathy.